IIUM Repository

Potential drugs for asthma allergy: in silico study and ADMET prediction of secondary metabolites derived from Curcuma longa Linn. rhizome

Pratama, Yusuf Alif and Marhaeny, Honey Dzikry and Rahmadi, Mahardian and Ozdemir, Kevser and Bardakci, Hilal and Hasan, Ahmed Abdallah and Kleuser, Burkhard and Bakhtiar, M. Taher and Khotib, Junaidi (2025) Potential drugs for asthma allergy: in silico study and ADMET prediction of secondary metabolites derived from Curcuma longa Linn. rhizome. Journal of Herbmed Pharmacology, 14 (4). pp. 496-503. E-ISSN 2345-5004

[img]
Preview
PDF - Published Version
Download (879kB) | Preview
[img]
Preview
PDF - Supplemental Material
Download (212kB) | Preview

Abstract

Introduction: An allergy is a hypersensitivity reaction generally mediated by the immune system, which is usually followed by an increase in IgE levels. The early phase of the molecular pathogenesis of allergies begins with the binding activation of the allergen and protease-activated receptor, followed by the phosphorylation of the three protein kinases. The role of p38 MAPK, ERK1/2, and JNK are integral to the pathophysiology of allergic asthma. Curcuma longa has been known as an anti-inflammatory herbal medicine that has a potential to be an asthma allergy drug. The in silico and absorption, distribution, metabolism, excretion, and toxicology (ADMET) prediction studies were conducted to identify the C. longa secondary metabolites as a potential asthma allergy drug. Those compounds suggest the molecular activity inhibition in the inflammatory pathways underlying allergic manifestations. Methods: Candidate compounds that fulfilled Lipinski’s theoretical requirements were docked to three protein kinases using Molegro Virtual Docker Version 5.5. The rerank score of each compound was compared with those of the standard ligand and existing drug. Results: At least two compounds with rerank scores consistently lower or comparable to the existing ligands and drugs, namely compound A (1,5-dihydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)-4,6-heptadien-3-one) and compound B (Bisdesmethoxycurcumin), were identified. The ADMET profile gave an outstanding result to be developed as a drug candidate. Conclusion: The secondary metabolites derived from C. longa exhibit potent inhibitory effects on those three kinases. This strategy seems to hold a significant potential for developing novel therapeutics targeting inhalant-induced allergies

Item Type: Article (Journal)
Uncontrolled Keywords: Curcuma species, Inhalant allergy, Noncommunicable disease, Molecular docking, Neglected tropical diseases
Subjects: R Medicine > RS Pharmacy and materia medica
R Medicine > RS Pharmacy and materia medica > RS192 Materia Medica-Pharmaceutical Technology
Kulliyyahs/Centres/Divisions/Institutes (Can select more than one option. Press CONTROL button): Kulliyyah of Pharmacy > Department of Pharmaceutical Technology
Depositing User: Dr Muhammad Taher
Date Deposited: 10 Dec 2025 10:00
Last Modified: 10 Dec 2025 10:00
Queue Number: 2025-12-Q532
URI: http://irep.iium.edu.my/id/eprint/125176

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year